Literature DB >> 31242994

Polatuzumab Vedotin Approved for DLBCL.

.   

Abstract

The antibody-drug conjugate polatuzumab vedotin has been approved to treat relapsed or refractory diffuse large B-cell lymphoma. The drug recognizes the CD79b protein on B cells and kills them with a molecule that prevents tubulin polymerization. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 31242994     DOI： 10.1158/2159-8290.CD-NB2019-076

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

1.  LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.

Authors:  Katherine K Slemmons; Sanjit Mukherjee; Paul Meltzer; James W Purcell; Lee J Helman
Journal:  Pediatr Blood Cancer       Date:  2020-10-16       Impact factor: 3.838

Review 2.  Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Leonard Jeff Harris; Kruti Patel; Michael Martin
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

3.  Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients.

Authors:  Melanie Douglas
Journal:  J Adv Pract Oncol       Date:  2020-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.